Kayentis

𝐋𝐢𝐯𝐞 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝟑𝟑𝐫𝐝 𝐁𝐕𝐌𝐀 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦! Björn Felber is at this key event in Germany. It’s a great opportunity to exchange ideas and help shape the future of patient-centric solutions! 👉 Are you attending? Let’s connect and share insights! #kayentis #eCOA #clinicalstudies #BVMA #innovation

𝐂𝐨𝐮𝐧𝐭𝐢𝐧𝐠 𝐝𝐨𝐰𝐧 𝐭𝐨 𝐭𝐡𝐞 𝐏𝐂𝐌𝐆 𝐀𝐈 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝟐𝟎𝟐𝟓 — 𝐣𝐮𝐬𝐭 𝐚 𝐟𝐞𝐰 𝐝𝐚𝐲𝐬 𝐭𝐨 𝐠𝐨! Catch Chris Barden next week at the AI Symposium hosted by the PCMG Clinical Outsourcing Community — a great opportunity to connect and exchange ideas! 👉 Want to meet Chris there? Schedule a meeting here: https://bit.ly/4m6x7k0 #kayentis #eCOA #clinicaltrials #PCMG

We're #hiring a new Software Quality & Risk Engineer M/F in Meylan, Auvergne-Rhône-Alpes. Apply today or share this post with your network.

𝐉𝐨𝐢𝐧 𝐨𝐮𝐫 𝐮𝐩𝐜𝐨𝐦𝐢𝐧𝐠 𝐰𝐞𝐛𝐢𝐧𝐚𝐫: 𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐁𝐘𝐎𝐃 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 – 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐨𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥 𝐒𝐮𝐜𝐜𝐞𝐬𝐬! As the Bring Your Own Device (BYOD) model gains momentum in clinical research, understanding what to consider and how to implement it effectively for electronic Clinical Outcome Assessment (eCOA) data collection is more crucial than ever. 👉 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐟𝐨𝐫 𝐚 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 𝐭𝐡𝐚𝐭 𝐞𝐱𝐩𝐥𝐨𝐫𝐞𝐬 𝐭𝐡𝐞 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐚𝐧𝐝 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐝𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐬 𝐨𝐟 𝐁𝐘𝐎𝐃 𝐚𝐝𝐨𝐩𝐭𝐢𝐨𝐧: https://bit.ly/4oRQiz9 Pascaline Richardot, Grace Gartel, Andrea Murison #kayentis #eCOA #clinicalstudies #BYOD #webinar

𝐂𝐨𝐮𝐥𝐝 𝐞𝐏𝐑𝐎𝐬 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐞𝐚𝐫𝐥𝐲-𝐩𝐡𝐚𝐬𝐞 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐭𝐫𝐢𝐚𝐥𝐬 𝐚𝐫𝐞 𝐫𝐮𝐧? In early-phase oncology trials, understanding patient experience is crucial. Our latest white paper explains why including PROs early on matters: 💊 Define dose-limiting toxicities (DLTs) and confirm the recommended Phase 2 dose (RP2D) 🔍 Detect lower-grade or new toxicities that might otherwise go unnoticed 🎯 Anticipate strategies for later-stage trials It also provides practical guidance for integrating PROs effectively into your early-phase oncology trials. 👉 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐰𝐡𝐢𝐭𝐞 𝐩𝐚𝐩𝐞𝐫 𝐡𝐞𝐫𝐞: https://bit.ly/3X17lT0 #kayentis #eCOA #clinicaltrials #oncology

𝐖𝐡𝐲 𝐬𝐡𝐨𝐮𝐥𝐝 𝐲𝐨𝐮 𝐮𝐬𝐞 𝐞𝐏𝐑𝐎 𝐢𝐧 𝐞𝐚𝐫𝐥𝐲-𝐩𝐡𝐚𝐬𝐞 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐭𝐫𝐢𝐚𝐥𝐬? Although early-phase trials have not traditionally been considered the primary setting for PROs, there are several compelling reasons to incorporate them into early-phase oncology clinical research. Swipe below to explore them 👇 #kayentis #eCOA #clinicalstudies #oncology #earlyphasetrials

We're #hiring a new Chef(fe) de Projet Clinique H/F - FR in Meylan, Auvergne-Rhône-Alpes. Apply today or share this post with your network.

𝐎𝐧𝐥𝐲 𝐚 𝐟𝐞𝐰 𝐝𝐚𝐲𝐬 𝐥𝐞𝐟𝐭 𝐮𝐧𝐭𝐢𝐥 𝐭𝐡𝐞 𝟑𝟑𝐫𝐝 𝐁𝐕𝐌𝐀 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦! We’re excited to share that Björn Felber will be representing us at this year’s event, focused on the competitiveness of clinical trials in Germany. Key themes include regulatory developments, innovation (including AI), and decentralized trials. 💡 A great opportunity to exchange with peers and contribute to the future of clinical research! 👉 If you’re attending — or interested in the topics being discussed — let us know: https://bit.ly/4m6x7k0 We’d love to connect! #kayentis #eCOA #clinicaltrials

𝐁𝐞𝐧𝐞𝐟𝐢𝐭 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐞𝐱𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐢𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬! Oncology trials pose unique challenges that make eCOA design and management more complex. With our proven tools and deep expertise, we help ensure your oncology studies run smoothly and successfully. 👉 Download the case study: https://bit.ly/3iGbs2J #kayentis #eCOA #clinicalstudies #oncology

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭-𝐫𝐞𝐩𝐨𝐫𝐭𝐞𝐝 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐬𝐨 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡? This is the central question explored in our article published in the Spring 2025 issue of International Clinical Trials (ICT): "𝐴𝑑𝑣𝑎𝑛𝑐𝑖𝑛𝑔 𝑂𝑛𝑐𝑜𝑙𝑜𝑔𝑦 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ: 𝑇ℎ𝑒 𝐶𝑟𝑢𝑐𝑖𝑎𝑙 𝑅𝑜𝑙𝑒 𝑜𝑓 𝑃𝑎𝑡𝑖𝑒𝑛𝑡-𝑅𝑒𝑝𝑜𝑟𝑡𝑒𝑑 𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑖𝑛 𝑃𝑎𝑡𝑖𝑒𝑛𝑡-𝐶𝑒𝑛𝑡𝑟𝑖𝑐 𝐷𝑒𝑐𝑒𝑛𝑡𝑟𝑎𝑙𝑖𝑧𝑒𝑑 𝐶𝑙𝑖𝑛𝑖𝑐𝑎𝑙 𝑇𝑟𝑖𝑎𝑙𝑠", authored by our Chief Medical Officer, Estelle Haenel. 🔎 The article examines why quality of life is a key endpoint in oncology trials, particularly decentralized ones, and how modern tools like electronic Clinical Outcome Assessments (eCOAs) can reduce the burden of data collection — making trials more accessible and more reflective of the patient experience. 👉 Find it in ICT Spring 2025, pages 24–27: http://bit.ly/46UNrz0 #kayentis #eCOA #PRO #oncology #clinicaltrials